The Wegovy pill is the first oral GLP-1 weight loss treatment approved in the UK. Wegovy pills contain the same semaglutide as the Wegovy pen, taken once daily with no injections, fridge storage, or pen equipment. Prescribed and dispensed through Phlo Clinic's GPhC-regulated pharmacy, with ongoing clinical support built in.
Lose up to 17% with our Wegovy weight loss service
Supported by UK-based clinical expertise and monthly check-ins
No hidden fees (pay-as-you-go)
*Buy your first 1.5mg Wegovy tablets at the starting price of £79, with subsequent 1.5mg orders increasing to £119 thereafter.
Wegovy tablets contain semaglutide, the same active ingredient as the Wegovy injection, and work by mimicking a natural hormone that signals to your brain when you're full, helping to reduce appetite and how much you eat.
The key difference from the injection is simply that the tablet is taken once-daily instead of a once-weekly injection. The tablet of course means no needles and there is also no refrigeration required.
Wegovy tablets were approved by the MHRA in June 2026, making the UK the first country in Europe to approve the world's first daily GLP-1 weight loss pill.
Tablet-based weight loss treatments
Contain semaglutide, a GLP-1 receptor agonist (the same active ingredient as Wegovy injections)
Taken once daily orally, rather than once weekly by injection
Clinically tested with results comparable to injectable options
A non-injectable alternative for those who prefer not to use a pen
Easier to fit into everyday life for some people
No refrigeration or injection equipment required
The same clinically-led approach, in a simpler format
Wegovy pills start from £89 for your first month, with pricing increasing gradually as your dose steps up through treatment. Every order includes free Tracked 24 delivery and ongoing clinical support, with no hidden fees.
*Get your first order of 1.5mg Wegovy tablets at the starting price of £79, with subsequent 1.5mg orders increasing to £119 thereafter.
*Discount codes will be auto-applied at checkout to reflect our 2 month bundle prices at these rates.
In a 64-week study (Oasis 4 phase 3 trial), people taking the Wegovy pill lost about 13.6% of their body weight on average. Those who took it consistently as prescribed lost more (around 16.6%). Results were comparable to those seen with the Wegovy injection in earlier trials, suggesting the tablet delivers similar clinical benefit despite the different delivery method.
average body weight lost across all the people who were given the tablet
of patients lost at least 10% of body weight
of patients lost at least 20% of body weight
*These are averages from a controlled clinical setting alongside a reduced-calorie diet and increased physical activity — individual results will vary.
Source - Wharton S, et al. Oral semaglutide 25mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077–1087.
* Averages from clinical trials in controlled settings alongside diet and lifestyle support. Individual results will vary.
* The two trials used different designs and durations and cannot be directly compared with each other.
* Wegovy tablets are now approved in the UK and available via private prescription. Subject to clinical assessment.
Wegovy tablets have a well-established safety profile, consistent with semaglutide in its injectable form, which has been used by millions of patients worldwide. In the OASIS 4 trial, serious adverse events were actually less common in the treatment group than in the placebo group (3.9% vs 8.8%), and fewer than 7% of patients stopped treatment due to side effects.
As with any prescription medicine, Wegovy tablets aren't suitable for everyone. They shouldn't be taken during pregnancy or breastfeeding, or by anyone who has had a serious allergic reaction to semaglutide. Some health conditions, including a history of pancreatitis or certain thyroid concerns, mean they may not be right for you, and they can interact with other medicines.
Our clinical team will review your full health history and assess your suitability before any prescription is issued
Clinically tested - approved by the MHRA following a phase 3 randomised controlled trial
Side effects are mostly mild - the most common are nausea and vomiting, typically during dose escalation, and settling down over time for most patients
Prescriber-led at Phlo Clinic - our clinicians will review your health history before prescribing and monitor you throughout treatment
Oral GLP-1 tablets and injectable GLP-1 treatments are both effective, clinically-proven options. The right choice depends on your personal preferences and circumstances. Here is a quick comparison:
* Averages from clinical trials in controlled settings alongside diet and lifestyle support. Individual results will vary.
* The two trials used different designs and durations and cannot be directly compared with each other.
* Wegovy tablets are now approved in the UK and available now via private prescription. Subject to clinical assessment.
Wegovy tablets follow a gradual four-step titration schedule, starting at a low dose of 1.5mg daily and increasing at a minimum every four weeks, giving your body time to adjust and helping to minimise digestive side effects like nausea. The full maintenance dose of 25mg once daily is typically reached by week 16 of treatment if you respond well, and is taken long-term to maintain weight loss results.
The tablet is taken once daily on an empty stomach, with a small amount of water, followed by a 30-minute wait before eating, drinking anything other than water, or taking other oral medicines. This fasting window is important for the medication to absorb properly.
| Phase | Daily dose | Duration |
|---|---|---|
Step 1 |
1.5mg
once daily |
Weeks 1-4 |
Step 2 |
4mg
once daily |
Weeks 5-8 |
Step 3 |
9mg
once daily |
Weeks 9-12 |
Step 4 |
25mg
once daily |
Week 13 onwards |
Your body begins adjusting to semaglutide. Mild nausea is common during this phase and usually settles quickly.
Appetite begins to reduce noticeably for most patients. Continue taking on an empty stomach each morning.
Weight loss typically becomes more consistent at this stage. Side effects, if any, are usually milder than in earlier weeks.
Full therapeutic dose for ongoing weight management. This is the dose used throughout the OASIS 4 clinical trial, in which patients lost an average of 13.6% of body weight.
Always follow the dosage instructions provided by your Phlo Clinic clinician and do not adjust your dose without speaking to a healthcare professional first.
Source: Novo Nordisk. Wegovy (semaglutide) tablet US prescribing information, 2026. Titration schedule based on FDA-approved labelling. UK dosing may vary subject to MHRA guidance.
Daily routine
Take first thing in the morning on an empty stomach, before eating or drinking anything other than water
Use a small amount of water, no more than around 120ml (4oz); do not take with other drinks
Wait 30 minutes before eating, drinking anything else, or taking other oral medicines; this allows the semaglutide to absorb properly
If you miss a dose, skip it and take your next tablet at the usual time the following day; do not take two doses to make up for a missed one
If you're currently taking the Wegovy 2.4mg weekly injection and want to switch to the tablet, you may be able to start at the full 25mg maintenance dose, skipping the titration steps entirely.
This would typically begin one week after your last injection, subject to a clinical review. If you're on a different injection dose, including the higher 7.2mg dose, switching to the tablet isn't a standard step and will need to be assessed individually by your prescriber. Either way, one of our prescribers will assess your suitability as part of a switching consultation.
Here's what joining means in practice:.
Be the first to know: we will email you when there are updates to our oral weight loss service
Clinician-led care: as with all Phlo Clinic treatments, you will receive ongoing support from our UK-registered clinical team
No need to keep checking: we will do the monitoring and reach out when there is a meaningful update
Trusted by thousands of patients: Phlo Clinic is a fully UK GPhC-regulated pharmacy
Expert guidance: our clinicians will help you understand whether oral GLP-1 treatment is right for you when it becomes available
The side effect profile of Wegovy tablets is broadly consistent with the Wegovy injection, most commonly affecting the digestive system, particularly in the early weeks of treatment while your dose is being increased. For the majority of patients, these effects are mild to moderate and improve as the body adjusts.
Nausea
The most commonly reported side effect, affecting around 47% of patients taking the tablet
Vomiting
Reported in around 31% of patients, most often when increasing dose
Diarrhoea
A known effect across the GLP-1 class, generally mild and short-lived
Constipation
Reported by some patients, particularly earlier in treatment
Pancreatitis
Rare but serious; seek urgent medical attention if you experience persistent severe abdominal pain
Gallbladder problems
Including gallstones, consistent with other GLP-1 medicines
Thyroid tumours
A precautionary warning on the box; do not take if you have a personal or family history of medullary thyroid cancer or MEN2. This was not observed in animal studies, but human relevance is unknown
The types of side effects are largely the same. Both are semaglutide and act on the same pathways.
The main practical difference is in how side effects are managed: the tablet requires a strict fasting protocol (taken on an empty stomach, with a 30-minute wait before eating & drinking), and nausea rates in the tablet trial were somewhat higher than those reported in injectable Wegovy trials.
However, serious adverse events were less common with the tablet in the OASIS 4 trial than with placebo.
How do the two treatments' side effects vary?
Nausea in ~47% of patients
Vomiting in ~31% of patients
Must be taken fasted, 30-min wait
No injection site reactions
Serious adverse events: 3.9%
Start consultation
Nausea in ~44% of patients
Vomiting in ~24% of patients
No fasting requirement
Possible injection site reactions
Serious adverse events: similar class profile
Available now
The tablet is not simply a like-for-like swap: the dosing is different (25mg oral tablet vs 2.4mg injectable), the fasting requirements are new, and your clinician will want to ensure you're stable on your current dose before any change is made.
At Phlo Clinic, the switching process would follow these steps:
Register for updates
We will email you when there are updates to our oral weight loss service
Complete a switching consultation
One of our prescribing pharmacists will review your treatment history, current dose, and health profile to confirm you're a suitable candidate to switch.
Receive your prescription
If approved, your clinician will prescribe Wegovy tablets at the appropriate starting dose for a switch. Please note, this may differ from your current injection dose.
Begin your tablet treatment
We'll guide you through how to take the tablet, how to manage side effects, dose escalation schedule, and provide monthly check-ins as well as support via our patient care team, 7 days a week.
